Biovance Capital Partners is a Portuguese life-sciences venture capital manager investing in early-stage biopharmaceutical companies across Europe, especially Southern Europe. It backs seed and Series A drug-development businesses across therapeutic areas and modalities, evaluating preclinical evidence, intellectual property and routes to clinical development. The team works with scientific founders and co-investors to build companies and advance potential treatments. Its industry partners include BIAL, whose expertise in epilepsy, Parkinson’s disease and rare diseases complements the fund’s broad therapeutic mandate; the fund retains independent investment decisions.
Founded
—
Type
Venture capital
Funds1
Biovance Capital Fund I FCRF€51M
Early-stage European biotechnology venture fund managed by Biovance Capital Partners, investing in seed and Series A drug-development companies with an emphasis on Southern Europe. It supports therapeutics across modalities and disease areas, including neuroscience.
